Valuation: Genovis AB

Market Cap 1.26B 129M 113M 105M 96.74M 181M 12.46B 185M 490M 6.09B 484M 473M 21.27B P/E 2026 *
49.9x
P/E 2027 * 30.9x
Enterprise Value 1.15B 118M 103M 95.89M 88.19M 165M 11.36B 169M 447M 5.55B 441M 432M 19.39B EV / Sales 2026 *
7.66x
EV / Sales 2027 * 5.81x
Free-Float
94.56%
Yield 2026 *
-
Yield 2027 * -
1 day-2.26%
1 week-0.52%
Current month-3.45%
1 month+4.62%
3 months-6.31%
6 months-12.75%
Current year-10.49%
1 week 18.44
Extreme 18.44
20.15
1 month 18.22
Extreme 18.22
21.2
Current year 15.64
Extreme 15.64
23.65
1 year 15.64
Extreme 15.64
29
3 years 15.64
Extreme 15.64
57.6
5 years 15.64
Extreme 15.64
90
10 years 1.66
Extreme 1.66
90
Manager TitleAgeSince
Chief Executive Officer 55 05/05/2015
Director of Finance/CFO 55 01/01/2022
Chief Tech/Sci/R&D Officer 42 01/01/2017
Director TitleAgeSince
Director/Board Member 77 01/01/2014
Director/Board Member 65 01/01/2019
Chairman 74 05/05/2020
Date Insider Type Main position Quantity % Market Cap.
15/05/26 Buy 4,146 0.0063%
24/02/26 Buy

Chief Financial Officer

2,470 0.0037%
24/02/26 Buy

Chief Financial Officer

3,137 0.0047%
Change 5-day change 1-year change 3-year change Capi.($)
-2.26%-0.52%-28.50%-55.56% 133M
-0.36%-7.83%+224.76%+298.83% 19.99B
-1.22%-3.97%-42.07%-27.84% 9.4B
-0.84%-0.57%+43.39%+18.49% 6.81B
+2.15%+5.05%+269.98%-19.85% 5.97B
-1.59%+8.49%-13.14%-23.02% 5.62B
-10.00%+9.69%+88.17%+110.73% 5.06B
+1.76%-10.37%-48.33% - 4.35B
-0.27%-3.80%-25.32%-28.44% 4.05B
-1.68%-0.86%-16.61%-39.76% 2.76B
Average -1.43%-2.27%+45.23%+25.95% 6.41B
Weighted average by Cap. -1.08%-3.57%+93.77%+98.95%

Financials

2026 *2027 *
Net sales 150M 15.36M 13.48M 12.52M 11.52M 21.61M 1.48B 22.01M 58.34M 725M 57.61M 56.36M 2.53B 189M 19.42M 17.04M 15.83M 14.56M 27.31M 1.87B 27.82M 73.74M 916M 72.82M 71.24M 3.2B
Net income 15.7M 1.61M 1.41M 1.31M 1.21M 2.27M 156M 2.31M 6.12M 76.07M 6.05M 5.91M 266M 38.9M 3.99M 3.5M 3.26M 2.99M 5.62M 386M 5.72M 15.17M 188M 14.98M 14.65M 658M
Net Debt -111M -11.4M -10M -9.29M -8.55M -16.03M -1.1B -16.33M -43.28M -538M -42.74M -41.82M -1.88B -158M -16.27M -14.28M -13.27M -12.2M -22.89M -1.57B -23.32M -61.81M -768M -61.03M -59.71M -2.68B
Logo Genovis AB
Genovis AB is a Sweden-based company engaged in the research and development, production and marketing of technologies and products for cellular research. The Company offers products within two product portfolios, namely protein portfolio and nano portfolio. The protein portfolio develops products within the areas of cancer, inflammatory and autoimmune diseases. The portfolio comprises FabRICATOR, a genetically modified enzyme the cleaves antibodies in two parts, and IgGZERO, a protein that specifically cleaves the sugar molecules that occur naturally on antibodies. The products within the nano portfolio are primarily directed at the preclinical market. The Company markets and sells its products through dealers and distributors in the European, North American and Asian continents. As of December 31, 2011, it operated a wholly owned subsidiary, Eijdo Research AB.
Employees
36
Date Price Change Volume
23/07/26 SEK 19.02 -2.26% 74,204
22/07/26 SEK 19.46 +0.93% 62,266
21/07/26 SEK 19.28 +0.21% 13,456
20/07/26 SEK 19.24 -3.80% 12,784
17/07/26 SEK 20.00 +5.71% 23,175
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
19.02SEK
Average target price
33.00SEK
Spread / Average Target
+73.50%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. GENO Stock